Evidence map›Paper›PMID 19892733›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2009

The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system.

Amyaouch Bradaia, Gerhard Trube, Henri Stalder, Roger D Norcross, Laurence Ozmen, Joseph G Wettstein, Audrée Pinard, Danièle Buchy, Martin Gassmann, Marius C Hoener and 1 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 247 citations in OpenAlex.

  1. Effect of TAAR1/5-HTTranslational psychiatry · 2021
    Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. GPCR Heterodimers: Implications for Biased Signaling.Handbook of experimental pharmacology · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Dopamine D1 receptor in medial prefrontal cortex mediates the effects of TAAR1 activation on chronic stress-induced cognitive and social deficits.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  19. TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  20. Review

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Amyaouch BradaiaDepartment of Biomedicine, Institute of Physiology, Pharmazentrum, University of Basel, CH-4056 Basel, Switzerland.
Gerhard Trube
Henri Stalder
Roger D Norcross
Laurence Ozmen
Joseph G Wettstein
Audrée Pinard
Danièle Buchy
Martin Gassmann
Marius C Hoener
Bernhard Bettler
Roche (Switzerland) · CHUniversity of Basel · CHCentre Paul Albert-Février · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trace amine-associated receptor 1 (TAAR1) is a G protein-coupled receptor (GPCR) that is nonselectively activated by endogenous metabolites of amino acids. TAAR1 is considered a promising drug target for the treatment of psychiatric and neurodegenerative disorders. However, no selective ligand to identify TAAR1-specific signaling mechanisms is available yet. Here we report a selective TAAR1 antagonist, EPPTB, and characterize its physiological effects at dopamine (DA) neurons of the ventral tegmental area (VTA). We show that EPPTB prevents the reduction of the firing frequency of DA neurons induced by p-tyramine (p-tyr), a nonselective TAAR1 agonist. When applied alone, EPPTB increases the firing frequency of DA neurons, suggesting that TAAR1 either exhibits constitutive activity or is tonically activated by ambient levels of endogenous agonist(s). We further show that EPPTB blocks the TAAR1-mediated activation of an inwardly rectifying K(+) current. When applied alone, EPPTB induces an apparent inward current, suggesting the closure of tonically activated K(+) channels. Importantly, these EPPTB effects were absent in Taar1 knockout mice, ruling out off-target effects. We additionally found that both the acute application of EPPTB and the constitutive genetic lack of TAAR1 increase the potency of DA at D2 receptors in DA neurons. In summary, our data support that TAAR1 tonically activates inwardly rectifying K(+) channels, which reduces the basal firing frequency of DA neurons in the VTA. We hypothesize that the EPPTB-induced increase in the potency of DA at D2 receptors is part of a homeostatic feedback mechanism compensating for the lack of inhibitory TAAR1 tone.

Indexed as

Limbic SystemReceptors, G-Protein-CoupledVentral Tegmental AreaAction PotentialsAnimalsBenzamidesDopamineG Protein-Coupled Inwardly-Rectifying Potassium ChannelsHumansMiceMice, KnockoutMolecular StructureNeuronsOocytesPatch-Clamp TechniquesPyrrolidinesBenzamidesDopamineG Protein-Coupled Inwardly-Rectifying Potassium ChannelsN-(3-ethoxyphenyl)-4-pyrrolidin-1-yl-3-trifluoromethylbenzamidePyrrolidinesReceptors, Dopamine D2Receptors, G-Protein-CoupledTrace Amine-Associated Receptors

Identifiers

PMID19892733
PMCPMC2785295
OpenAlexW2085926691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.